People: Solazyme Inc (SZYM.O)

SZYM.O on Nasdaq

2.76USD
21 Nov 2014
Price Change (% chg)

$-0.15 (-5.15%)
Prev Close
$2.91
Open
$3.00
Day's High
$3.01
Day's Low
$2.67
Volume
3,360,930
Avg. Vol
1,860,148
52-wk High
$15.00
52-wk Low
$2.67

Search Stocks

Clark, Ian 

Brief Biography

Mr. Ian T. Clark is Independent Director of Solazyme Inc. Mr. Clark currently serves as chief executive officer of Genentech, Inc., a member of the Roche Group, and head of North American Commercial Operations. He was appointed to this role in January 2010. Mr. Clark also leads the Genentech executive committee and is a member of the Genentech board of directors. Mr. Clark joined Genentech in 2003 as senior vice president and general manager, BioOncology. In August 2005 he was named senior vice president, Commercial Operations and became a member of the executive committee, and in January 2006, he was named executive vice president, Commercial Operations. In April 2009, he was named head of Global Product Strategy and chief marketing officer. Prior to joining Genentech, Mr. Clark served as president of Novartis Canada, overseeing all of the company’s country operations. Before assuming his post in Canada, Mr. Clark served as chief operating officer for Novartis United Kingdom. Prior to joining Novartis in 1999, Mr. Clark worked in vice presidential roles in sales and marketing for Sanofi (Aventis) and Ivax in the United Kingdom and Eastern Europe. Mr. Clark has served on the board of the Biotechnology Industry Organization (BIO) Industry Association since 2009, is an advisor to the Institute of Life Sciences at Southampton University in the United Kingdom, and is a member of the Federal Reserve Bank of San Francisco’s Economic Advisory Council. Mr. Clark received a Bachelor of Science degree in biological sciences from Southampton University in the United Kingdom.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Jerry Fiddler

--

Jonathan Wolfson

3,477,950

Tyler Painter

1,926,360

Peter Licari

1,925,580

Paul Quinlan

1,229,730

James Craigie

--
As Of 30 Dec 2013
Search Stocks